| Role of integrated 18-fluorodeoxyglucose position emission tomography-computed tomography in patients surveillance after multimodality therapy of malignant pleural mesothelioma. | |
| | |
MedLine Citation:
|
PMID: 20087231 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
INTRODUCTION: To investigate the role of 18-fluorodeoxyglucose positron emission tomography-computed tomography (18-FDG-PET-CT) in the surveillance of patients after multimodality treatment of malignant pleural mesothelioma. METHODS: Retrospective study of patients who had chemotherapy, radical surgery, extrapleural pneumonectomy or pleurectomy/decortication, and radiotherapy for mesothelioma in our unit. PET-CT was performed after multimodality therapy to evaluate response to treatment or when disease recurrence was suspected. 18-FDG-PET scans were acquired from skull base to upper thigh with low-dose CT scans for attenuation correction and image fusion. RESULTS: Forty-four patients had extrapleural pneumonectomy (21) or pleurectomy/decortication (23) between January 2004 and July 2008. Twenty-five patients had PET-CT performed after multimodality therapy. This was performed in 11 patients in whom disease recurrence was suspected at a median of 9 (range, 6-16) months after treatment. PET-CT correctly diagnosed recurrent disease in eight patients and missed microscopic recurrence in one. Surveillance PET-CT was performed in 14 asymptomatic patients at a median of 11 (range, 7-13) months after treatment. It showed unsuspected recurrences in four patients. The standard uptake value max of recurrent mesothelioma was 8.9 +/- 4.0 (4-18.4). PET-CT had a sensitivity of 94%, a specificity of 100%, and the positive and negative predictive values of 100 and 88%, respectively. CONCLUSIONS: 18-FDG-PET-CT is useful in diagnosing disease recurrence after multimodality therapy for malignant pleural mesothelioma. We propose a prospective study to fully assess its value in this group of patients. |
| | |
Authors:
|
Carol Tan; Sally Barrington; Sheila Rankin; David Landau; John Pilling; James Spicer; Paul Cane; Lo?c Lang-Lazdunski |
Publication Detail:
|
Type: Journal Article |
Journal Detail:
|
Title: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer Volume: 5 ISSN: 1556-1380 ISO Abbreviation: J Thorac Oncol Publication Date: 2010 Mar |
Date Detail:
|
Created Date: 2010-02-26 Completed Date: 2010-05-27 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 101274235 Medline TA: J Thorac Oncol Country: United States |
Other Details:
|
Languages: eng Pagination: 385-8 Citation Subset: IM |
Affiliation:
|
Department of Thoracic Surgery, Guys and St Thomas' Hospital, London SE1 9RT, United Kingdom. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Aged Antineoplastic Agents / therapeutic use Chemotherapy, Adjuvant Combined Modality Therapy Female Fluorodeoxyglucose F18 / diagnostic use* Humans Male Mesothelioma / radiography*, radionuclide imaging*, therapy Middle Aged Neoplasm Recurrence, Local / radiography, radionuclide imaging, therapy Pleural Neoplasms / radiography, radionuclide imaging, therapy Population Surveillance Positron-Emission Tomography* Radiopharmaceuticals / diagnostic use Radiotherapy Dosage Retrospective Studies Survival Rate Tomography, X-Ray Computed* Treatment Outcome |
| Chemical | |
Reg. No./Substance:
|
0/Antineoplastic Agents; 0/Radiopharmaceuticals; 63503-12-8/Fluorodeoxyglucose F18 |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Expression of Class III Beta-Tubulin Correlates with Unfavorable Survival Outcome in Patients with R...
Next Document: Pelvic sentinel lymph node biopsy in melanoma patients: is it worthwhile?